Healthcare ranking
Top 10 MASH and fatty liver disease clinical trial sponsors 2026
GSK started the most MASH and fatty liver disease clinical trials as lead sponsor between November 2023 and October 2026, with 9 trials. The list ranks companies worldwide by the number of new interventional trials they lead in this area.
Top 10 at a glance
The full list
| Rank | Company | Headquarters | new industry-sponsored clinical trials (trials) |
|---|---|---|---|
| 1 | GSK | United Kingdom | 9 |
| 2 | Boehringer Ingelheim | Germany | 5 |
| 2 | Regeneron | United States | 5 |
| 4 | Roche | Switzerland | 4 |
| 4 | Madrigal Pharmaceuticals | United States | 4 |
| 6 | Merck & Co. (MSD) | United States | 3 |
| 6 | Novo Nordisk | Denmark | 3 |
| 6 | Akero Therapeutics | United States | 3 |
| 6 | Eccogene | China | 3 |
| 6 | Xiamen Amoytop Biotech | China | 3 |
How this list is built
We counted interventional clinical trials with a company as lead sponsor and a start date from 1 November 2023 to 31 October 2026 that list MASH and fatty liver disease as a studied condition; withdrawn trials are not counted. Subsidiaries and name variants are merged into the parent company ("Hoffmann-La Roche" and "Genentech, Inc." are counted as Roche), and hospitals, universities and other non-company sponsors are left out. Companies with the same count share a rank, and all companies tied at the last place are shown.
Every position is set by the data alone, by the same rules for every company. Spotted something to update? Write to info@stratummarketresearch.com with the list and the line, and we correct it within two working days.
For ranked companies: a free badge
Ranked companies can show this badge on their website, in a press release or on LinkedIn at no cost. Pick your company, then copy the code.
Frequently asked questions
Who is number one in the MASH and fatty liver disease clinical trial sponsors ranking?
GSK ranks first with 9 trials (November 2023 to October 2026).
How is this ranking calculated?
We counted interventional clinical trials with a company as lead sponsor and a start date from 1 November 2023 to 31 October 2026 that list MASH and fatty liver disease as a studied condition; withdrawn trials are not counted. Subsidiaries and name variants are merged into the parent company ("Hoffmann-La Roche" and "Genentech, Inc." are counted as Roche), and hospitals, universities and other non-company sponsors are left out. Companies with the same count share a rank, and all companies tied at the last place are shown.
Can a company pay to rank higher?
Positions come only from the counts described above, and inclusion is free. Every company is ranked by the same rules.
How often is the ranking updated?
Every list is recomputed each quarter from the latest public records, and the update date is printed on the page.
Can a ranked company use the badge?
Yes. Every ranked company can use the free web badge on this page on its website, in press releases and on social media.
Custom research
Looking for a specific market?
Tell us the market, the region and the decision you are making. We reply within one working day with a scope and a date.